Targeted MET inhibition after progression with osimertinib

Despite the success of osimertinib, a third-generation EGFR-TKI, in first-line therapy, the treatment of NSCLC after progression remains a challenge. SAVANNAH and ORCHARD have investigated the targeted addition of additional agents to osimertinib after disease progression during first-line treatment with osimertinib.